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Abstract Chronic migraine (CM) and episodic migraine
(EM) are part of the spectrum of migraine disorders, but
they are distinct clinical entities. Population-based studies
have shown that those with CM demonstrate higher
individual and societal burden because they are significant-
ly more disabled than those with EM and have greater
impaired quality of life both inside and outside the home.
Proper diagnosis of both conditions requires clearly defined
clinical criteria. Diagnosis enables the initiation of appro-
priate treatments and risk-factor modification, which ulti-
mately improve functional status and quality of life for
persons with migraine. Recognizing that both disorders are
on the spectrum of migraine, this review serves as a guide
to define the disease state of CM as distinct from EM in
terms of clinical, epidemiological, sociodemographic, and
comorbidity profiles.
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Introduction
Migraine is a debilitating headache disorder. Including both
episodic and chronic forms, it affects 14% of the popula-
tion, and up to 18% of women [1, 2]. Migraine is currently
ranked by the World Health Organization (WHO) as 19th
among causes for years lived with disability [1]. Given the
current barriers, improving diagnosis and optimizing
treatment paradigms could substantially reduce this global
burden.
Because there are no biological markers for migraine,
diagnosis is based on clinical history and the exclusion of
other headache disorders. Health care professionals apply
clinical criteria to guide diagnoses and subsequent treat-
ment. The definition of migraine without aura from the
second edition of the International Classification of Head-
ache Disorders (ICHD-2) requires all of the following
symptoms: a) recurrent headaches (at least 5 lifetime
attacks); b) untreated or unsuccessfully treated headache
duration of 4 to 72 h; and c) at least two of the following
pain characteristics: unilateral, pulsating, moderate or
severe intensity, or aggravated by routine physical activity.
In addition, the migraine attacks are associated with at least
one of nausea/vomiting, photophobia, or phonophobia.
Finally, other causes of headache must be excluded [3].
Episodic migraine (EM) is characterized by those with
migraine who have 0 to 14 headache days per month, while
chronicmigraine(CM)ischaracterizedby15ormoreheadache
days per month. Specifically, revised ICHD-2 (ICHD-2R)
criteria define CM as headache on 15 or more days per month
for 3 or more months, of which 8 or more days meet criteria for
migraine without aura and/or respond to migraine-specific
treatment, occurring in a patient with a lifetime history of at
least five prior migraine attacks not attributed to another
causative disorder and no medication overuse [4].
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progresses to CM at the rate of 2.5% per year [5], and CM
often remits to EM (2-year transition rate of 26%) [6]. The
use of a frequency score of 15 or more days per month to
classify CM is admittedly somewhat arbitrary. Nonetheless,
these clinical definitions identify groups that differ in
epidemiologic and symptom profiles, functional consequen-
ces and disabilities, indirect and direct costs, patterns of
consultation and treatment, and rates of comorbidities. In
addition, the patterns of treatment response for EM and CM
differ, raising the possibility of both overlapping and
distinct biological mechanisms.
Large observational studies have provided valuable
information on the distinct clinical characteristics observed
in CM and EM [7￿￿, 8￿￿, 9, 10￿￿]. Much of the recently
published data that highlight the epidemiological distinction
between CM and EM have been generated by three large
observational studies: the International Burden of Migraine
Study (IBMS), the American Migraine Prevalence and
Prevention (AMPP) study, and the German Headache
Consortium (GHC) study. IBMS is a web-based, cross-
sectional, multinational survey that identified and evaluated
persons with CM and persons with EM [7￿￿]. The AMPP
study is a large United States (US) population–based, mail-
based, longitudinal survey that identified 24,000 respond-
ents with headache and followed them annually for 5 years
(2004–2009) [8￿￿]. The GHC study is a German popula-
tion–based longitudinal survey where respondents complet-
ed questionnaires via mail (n=4642) or phone (n=4708)
and were identified as either CM, high-frequency EM (9–14
headache d/mo), or low-frequency EM (0–8h e a d a c h ed / m o )
and then evaluated on an annual basis [10￿￿].
Herein and with an emphasis on recent key findings, this
article provides an update on the similarities and differences
between CM and EM in their epidemiologic and symptom
profiles, functional consequences and disabilities, indirect
and direct costs, patterns of consultation and treatment, and
rates of comorbidities.
Epidemiology of Chronic Migraine Versus Episodic
Migraine
Prevalence
Epidemiologic studies in Europe and America estimate that
6% to 8% of men and 15% to 18% of women experience
migraine each year [1]. Recent prevalence data from the US
population–based AMPP study reported the 1-year gender-
stratified prevalence for EM was 17.1% for women and
5.6% for men [11], and for CM was 1.3% for women and
0.5% for men [12]. CM prevalence rates also varied by age,
and were highest for women (1.9%) and men (0.8%) in the
age range of 40 to 49 years. The authors also reported that
CM represents 7.7% of the total migraine population [12].
Definitional variability of CM poses an epidemiological
challenge; however, a recent systematic review summariz-
ing 12 population-based studies using several definitions
for frequent migraine determined the global prevalence of
CM to be from 0.0% to 5.1% in the general population,
with most estimates in the range of 1.4% to 2.2% [13￿].
Most of the reviewed studies used the definition of chronic
daily headache (≥ 15 headache/mo) with ICHD-1 migraine
criteria [14] or the Silberstein-Lipton criteria for CM [15,
16]. None of these criteria matched the current ICHD-2R
criteria [4, 13￿], at least in part because of difficulties
implementing the criteria.
Symptom Profiles
The IBMS provides the most robust epidemiological data
comparing the symptom profiles of CM and EM (Table 1)
[7￿￿]. Findings demonstrated that, on average, persons with
CM had longer duration of headache attacks than those
with EM, both treated (24.1 vs 12.8 h; P<0.0001) and
untreated (65.1 vs 38.8 h; P<0.0001) [3, 4, 7￿￿, 8￿￿, 17]. In
addition, chronic migraineurs were more likely to experi-
ence severe pain intensity than episodic migraineurs [7￿￿].
These population findings are confirmed by clinic-based
data. For example, the Phase 3 Research Evaluating
Migraine Prophylaxis Therapy (PREEMPT) clinical pro-
gram [18] characterized 1384 individuals as chronic
migraineurs. In a 28-day baseline period, headache oc-
curred on 20 days on average, with 19 migraine days and
18 moderate/severe headache days [18].
Sociodemographics
The AMPP study and the IBMS demonstrated different
sociodemographic findings between persons with EM and
CM [7￿￿, 8￿￿]. Both studies demonstrated that CM and EM
were most common among females in their fourth decade
of life, although those with CM were slightly older (AMPP:
CM=41.7 y [mean] vs EM=40.2 y [mean], P=0.005;
IBMS: CM=47.7 y [mean] vs EM=46.0 y [mean], P=0.03
[Table 1]) [7￿￿, 8￿￿]. CM also was most common among
Caucasians (over 80%) [7￿￿, 8￿￿]. However, sociodemo-
graphic profiles for persons with CM differed from EM in
that those with CM reported significantly lower household
income levels, were less likely to be employed full time,
and were more likely to be occupationally disabled (Table 1)
[8￿￿]. In the GHC study, chronic migraineurs also were
found to have significantly higher body mass index (BMI;
CM=25.9 mean BMI vs EM=24.1 mean BMI, P<0.015),
have achieved lower levels of education, and were more
likely to be smokers [10￿￿].
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CM has been shown to impose a greater emotional and social
burden on the individual than EM in large observational
studies using various validated tools [7￿￿, 9, 19]. Using the
Migraine-Specific Quality of Life (MSQ) questionnaire,
which details how migraines limit daily performance, the
IBMS showed individuals with CM consistently scoring
worse in all categories by 6 to 13 points compared to
individuals with EM [7￿￿]. The 2009 AMPP study used the
Headache Impact Test-6 (HIT-6) to assess headache impact
on the lives of chronic migraineurs [19]. Conversion of HIT-
6s c o r e st os t a n d a r dc a t e g o r i e sr e v e a l e dt h a ti n d i v i d u a l sw i t h
CM were much more likely to experience severe headache
impact (72.9%) than those with EM (42.3%) [19]. Further-
more, those with CM had significantly higher odds of
adverse headache impact than those with EM (OR 3.5; 95%
CI, 2.77–4.41; P<0.0001) [19]. The AMPP study also
evaluated disability and similarly showed that those with
CM had a greater disability according to the Migraine
Disability Assessment (MIDAS) questionnaire [9], which
calculates a disability score based on reduced productivity
(eg, missed days of school and work).
Economic Burden
In the 2005 AMPP study data, CM respondents had lower
household income levels, were nearly twice as likely to be
occupationally disabled (CM 20.0% vs EM 11.1%; P<
0.001), and were less likely to be employed full time than
EM respondents (CM 37.8% vs EM 52.3%; P<0.001)
[8￿￿]. In the 2006 AMPP study data, more than half of the
individuals with CM missed at least 5 days of household
work over a 3-month period, compared with only one
quarter of those with EM [9]. Chronic migraineurs were
three times more likely to report reduced productivity in
household work than those with EM (58.1% vs 18.2%; P<
0.001) [9]. A minimum of 5 days of missed family
activities was reported by 36.9% of those with CM and
only 9.5% of those with EM (P<0.001) [9].
In another analysis of the 2005 AMPP study, chronic
migraineurs were 19% less likely to be working for pay and
lost 4.6 h per week from headache compared to 1.1 h by those
with 3 or fewer headache days per month [20]. Although
those with high-frequency migraine (10–14 headache d/mo)
or CM only accounted for 9.1% of employed migraineurs,
they represented 35% of the overall lost work time when
consideringmedicalleaveandunemployment[20]. According
to the 2006 AMPP study, those with CM have reported work
or school productivity to be reduced by over 50% in the
previous 3 months because of headaches [21].
From a societal perspective, CM is more costly per
individual than EM [7￿￿, 21, 22]. Both the AMPP study and
IBMS found that those with CM had a statistically
significant increase in resource utilization, as evidenced
by markedly more primary care visits, specialist visits,
emergency room visits, and hospitalizations compared to
those with EM [7￿￿, 21, 22]. Regarding US estimates, the
Table 1 Profiles of persons
with chronic migraine and
episodic migraine
*Indicates statistical significance
(P<0.05) between episodic and
chronic migraine
aInternational Classification of
Headache Disorders-2 [3]
bInternational Classification of
Headache Disorders-2,
revised [4]
cBlumenfeld et al. [7￿￿]
dBuse et al. [8￿￿]
eBigal et al. [17]
fMeasured by the Patient Health
Questionnaire-9
BMI body mass index, SD
standard deviation
Patient profiles Chronic migraine Episodic migraine
Clinical characteristics
a, b, c
Headache frequency, d/mo ≥ 15 < 15
Severe headache pain,% 92.4
* 78.1
Duration of headache without medication, mean h 65.1
* 38.8
Duration of headache with medication, mean h 24.1
* 12.8
Sociodemographics
d
Mean age, y (SD) 47.7
* (14.0) 46.0 (13.8)
Race,% Caucasian 90.7 87.3
Women,% 78.6 80.0
Occupationally disabled,% 20.0
* 11.1
Household income,%<$22,500/y 29.9
* 24.9
Mean BMI, n (SD) 29.8 (8.3) 29.2 (7.9)
Resource utilization
c
Primary care provider visits,% 48.0
* 26.4
Neurology/headache specialist visits,% 23.8
* 8.0
Comorbidities
d, e
Depression
f,% 30.2
* 17.2
Anxiety,% 30.2
* 18.8
Obesity,% 25.5
* 21.0
Cutaneous allodynia,% 68.3
* 63.2
88 Curr Pain Headache Rep (2012) 16:86–92average per-person annual total costs were more than
fourfold greater for those who had progressed to CM
($7750) compared with EM ($1757) [21].
Comorbidities
Those with various types of migraine share a range of
comorbidities. Recent observational studies have provided
insight into the distinct comorbidity profiles of those with
CM versus EM. The IBMS demonstrated that those with
CM were significantly more likely to report comorbidities
for all groups than EM, notably in nonheadache pain (CM
39.1% and EM 18.4%; P<0.0001), psychiatric disorders
(CM 46.3% and EM 28.5%; P<0.0001), and vascular
disease events (CM 8.2% and EM 3.3%; P<0.0001) [7￿￿].
Similarly, the AMPP study [8￿￿] revealed that those with
CM were about twice as likely to be depressed (CM 30.2%
vs EM 17.2%; OR 2.0; 95% CI, 1.67–2.40; P<0.001) as
determined by self-report on the Patient Health
Questionnaire-depression module (PHQ-9) [23] and to have
anxiety based on self-report of a physician’s diagnosis (CM
30.2% vs EM 18.8%; OR 1.8; 95% CI, 1.51–2.15; P≤0.001
[Table 1]). Chronic pain disorders also were more than
twice as frequent among persons with CM (31.5% vs
15.1%; OR 2.5; 95% CI, 2.08–2.97; P≤0.001) as well as
specific pain disorders like arthritis (CM 33.6% vs EM
22.2%; OR 1.7; 95% CI, 1.43–2.05; P≤0.001). In addition,
the CM population also had higher rates of cardiovascular
and respiratory comorbidities, such as hypertension, high
cholesterol, stroke, emphysema or chronic obstructive
pulmonary disease, and asthma [8￿￿].
Onset and Risk Factors for Progression from Episodic
Migraine to Chronic Migraine
Epidemiological and clinical observations support the
progression of EM to CM [24] Progression from EM to
CM occurs in about 2.5% of those with EM annually [5].
Because not all those with EM progress to CM, it is
important to identify those at high risk for progression. Risk
factors can be broken into two categories: those that are
easily modified and those that are not readily modifiable
(eg, age, female sex, Caucasian race, low educational level/
socioeconomic status, and head injury) [25]. Identification
of modifiable risk factors for progression to CM, such as
obesity, depression, and medication overuse, is important
because physicians can implement approaches through
behavioral and pharmacologic interventions to help the
patient maintain a stable, healthy lifestyle, thus reducing the
risk of CM [26]. Below are brief discussions of potential
modifiable risk factors and their associations with the
transition between EM and CM.
Modifiable Risk Factors
Studies have linked obesity to frequent headache [26].
Although obesity (defined as having BMI>30) is not a risk
factor for the development of EM, it is a risk factor for
progression of EM to CM [26]. One large population-based
study reported that the prevalence of CM ranged from 0.9%
in normal-weighted persons to 1.6% in the obese population
(OR1.7[1.2–2.4])and2.5%inthemorbidlyobesepopulation
(OR 2.2 [1.5–3.2]) [27].
Depression, anxiety, and chronic pain disorders all have
beenassociatedwithCMathigherrates thanwith EM [8￿￿]. It
has been difficult to determine the causal relationship
between depression and migraine because there is a
bidirectional relationship between the two disorders; thus,
those experiencing either migraine or depression are at
increased risk for developing the other [28]. To explain this
relationship, two possible hypotheses are depression as a risk
factor for CM onset or depression as a consequence of CM
[29]. However, recently presented results support a casual
rather than consequential relationship between depression
and the onset of CM. Adjusted longitudinal modeling of the
AMPP study data aimed to assess the role of depression as a
predictor of new onset of CM among persons with EM and
concluded that, among persons with EM, severe depression
was associated with an about 1.28-fold increased risk of the
subsequent onset of CM the following year, even after
controlling for factors of headache-related disability and
headache-day frequency [29]. Additionally, the effects of
depression, anxiety, and obesity are additive, such that
migraine-related disability increases when obese individuals
have comorbid depression or anxiety compared to non-
depressed obese migraineurs [30, 31].
Stressful life events such as divorce, moving, employ-
ment changes, or problems with children have been
considered a risk factor for chronic daily headache [32].
Results from the frequent headache epidemiology study
demonstrated that, compared to episodic headache control
patients, those with chronic daily headache had more major
life changes in the year before or the same year as the onset
of chronic daily headache [32].
Traditionally, acute medication overuse (generally de-
fined as use of medications on more than 10 or 15 d/mo,
depending on the class) [5] has been considered a risk
factor for poor migraine prognosis [33, 34]. Recent
epidemiological data have shown that intake of (overuse
or use of) certain classes of medication increase the risk of
CM in those who already have EM. Specifically, follow-up
data from respondents in the 2006 AMPP study demon-
strated that those with EM in 2005 had an increased risk of
developing CM when they used compounds that contained
barbiturates (OR 2.06; 95% CI, 1.3–3.1) and opiates (OR
1.98; 95% CI, 1.4–2.8) [5]. The use of triptans or NSAIDs
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[5]. These findings support other population-based [35–37]
and clinic-based studies [34] in chronic daily headache.
Another possible risk factor for progression to CM is the
consumption of caffeine. A population-based study that
investigated caffeine consumption among participants in a
general health survey determined that high medicinal (first-
choice medication containing caffeine) or dietary (287 mg/d)
consumption of caffeine before chronic daily headache onset
was a modest risk factor (OR 1.5; P=0.05), with an increase
in women (OR 1.9; P=0.006) and those who were under
40 years (OR 3.4; P<0.001) [38].
Risk-factor modification, such as decreasing headache
frequency with behavioral and pharmacological treatment;
weight loss management; avoiding medication overuse and
caffeine consumption; and screening and treating depression
and other psychiatric comorbidities, remains a component to
optimizing care [26].
Patterns of Treatment Response
Acute Treatment
Acute medication is often required because migraine attacks
are associated with severe and disabling features and usually
are accompanied by other symptoms of sensory disturbance
(eg, light and sound sensitivity) [39]. Because the clinical
distinction between CM and EM is based primarily on the
frequency of headache and migraine days rather than the
attack features or symptoms, both populations use acute
therapies (eg, analgesics and NSAIDs) or migraine-specific
agents with vasoconstrictor properties (eg, triptans and ergot
derivatives) [9, 39]. Although the patterns of treatment
response to acute medication are similar between EM and
CM, there are emerging differences driven by the frequency
of use, response, and overall satisfaction [9]. It is important
to treat CM and EM patients at the earliest onset of
symptoms; however, those with CM have a less robust
response to triptans than those with EM [40￿]. Additionally,
medication overuse of acute therapies containing barbiturates
and opiates is a risk factor and an important consideration,
particularly for CM [5]. It is critical to limit and monitor the
use of these compounds when treating migraine and to
educate patients on the risks associated with the progression
to CM due to medication overuse.
Preventive Treatment
As our understanding of the clinical, epidemiological, and
pathophysiological differences between EM and CM
develops, it becomes highly likely that we will find the
patterns of treatment or treatment response to preventive
therapies to be different between the two migraine groups.
Indeed, the recognition of the two disease states within the
ICHD-2 guidelines is designed to facilitate the optimal
treatment paradigm and the development of therapies
specifically targeted at either EM or CM.
Several classes of drugs are available for migraine
prevention, including antihypertensives, antiepileptics, and
antidepressants [39]. Specifically, antihypertensive agents
available for migraine treatment are β-blockers, angiotensin-
converting enzyme inhibitors, angiotensin receptor blockers,
and calcium channel blockers. Common choices of antiepi-
leptics include topiramate, valproate, and gabapentin. In
addition, tricyclic antidepressants are commonly used [39].
Many of these therapies also are used in the prevention
of CM; however, of the aforementioned EM therapies, only
topiramate has demonstrated efficacy in CM patients
through randomized placebo-controlled trials [41, 42].
Additionally, while efficacy has not been demonstrated in
EM, onabotulinumtoxin A injections [43] have demonstrat-
ed safety and efficacy in CM patients in randomized,
double-blind, placebo-controlled studies [18, 44, 45]. Less-
studied agents in CM preventive treatment include gaba-
pentin, pregabalin, fluoxetine, tizanidine, zonisamide, and
memantine [46].
Conclusions
Migraine is a highly debilitating disease in both its episodic
and chronic forms, with the latter imposing more substan-
tial individual and socioeconomic burden as described by
various population-based studies [7￿￿, 9, 10￿￿, 21]. Through
identification of risk factors for progression to CM,
clinicians can educate patients about modifiable risk factors
and can begin appropriate selected therapy in a timely
manner. As research continues to demonstrate, CM is a
distinct disorder with clinico-epidemiological profiles and
therapeutic response patterns different from that of EM.
Clear definition and enhanced recognition of these two
disease states can better facilitate the development of
therapies specifically targeted at either EM or CM.
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